AHA GUIDELINES Bundle (free trial)

Dyslipidemia 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1543908

Contents of this Issue

Navigation

Page 72 of 105

73 4.2.8.5. Considerations Based on Ancestry Table 21. Considerations According to Ancestry Groups Observed Higher Risk in Demographic Groups • South Asian ancestry is a high-risk demographic group and considered a risk enhancer. • Increased prevalence of diabetes at lower BMI and waist circumferences across Asian populations. • Increased CKM syndrome risk factors among Filipino American individuals, including hypertension, hyperlipidemia, and obesity. Variation in Lipid Measures • Higher levels of Lp(a) are found in non-Hispanic Black individuals, but associated increase in CVD relative risk is similar to other groups. • Elevated Lp(a) is associated with a higher population-attributed risk for MI among South Asian and Latin American people. • Baseline CK levels are higher in non-Hispanic Black individuals but may not portend greater risk for statin-associated adverse events. Statin Sensitivity • Some individuals of Chinese, Japanese, or Korean ancestry have been observed to have higher plasma concentrations of rosuvastatin, resulting in heightened sensitivity, and may benefit from starting rosuvastatin therapy at a lower dose. BMI indicates body mass index; CK, creatine kinase; CVD, cardiovascular disease; Lp(a), lipoprotein (a); and MI, myocardial infarction. 4.2.8.6. Adults With Heart Failure COR LOE Recommendation 3: No Benefit A 1. In adults with HFrEF who do not have clinical ASCVD or another indication for LLT, initiation of LLT is not recommended to reduce clinical events or mortality.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Dyslipidemia 2026